Home/Filings/4/0002045027-25-000003
4//SEC Filing

Davis Hugh M. 4

Accession 0002045027-25-000003

CIK 0001557746other

Filed

Dec 3, 7:00 PM ET

Accepted

Dec 4, 4:50 PM ET

Size

7.3 KB

Accession

0002045027-25-000003

Insider Transaction Report

Form 4
Period: 2025-12-02
Davis Hugh M.
DirectorPresident and COO
Transactions
  • Exercise/Conversion

    Common Stock

    2025-12-02+26,75026,750 total
  • Exercise/Conversion

    Restricted Stock Units

    2025-12-0226,75080,250 total
    Common Stock (26,750 underlying)
Footnotes (2)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
  • [F2]The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of December 2, 2024 (in each case rounded down to the nearest whole share, except for the last vesting installment), subject to the Continuous Service (as defined in the Issuer's 2024 Inducement Plan) of the Reporting Person as of each such date.

Issuer

Aclaris Therapeutics, Inc.

CIK 0001557746

Entity typeother

Related Parties

1
  • filerCIK 0002045027

Filing Metadata

Form type
4
Filed
Dec 3, 7:00 PM ET
Accepted
Dec 4, 4:50 PM ET
Size
7.3 KB